Febuxostat for the treatment of hyperuricaemia in gout
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2018.1498842
Abstract: ABSTRACT Introduction: Febuxostat is a potent non-purine selective xanthine oxidase inhibitor approved by the FDA in 2009 for management of hyperuricemia in people with gout. Areas covered: The authors summarize the pre-clinical studies and pivotal… read more here.
Keywords: gout; febuxostat; treatment hyperuricaemia; hyperuricaemia gout ... See more keywords